# Trial of CUDC-907 in Children and Young Adults With Relapsed or Refractory Solid Tumors, CNS Tumors, or Lymphoma

> **NCT02909777** · PHASE1 · COMPLETED · sponsor: **Dana-Farber Cancer Institute** · enrollment: 26 (actual)

## Conditions studied

- Lymphoma
- Neuroblastoma
- Brain Tumor
- Solid Tumor

## Interventions

- **DRUG:** CUDC-907

## Key facts

- **NCT ID:** NCT02909777
- **Lead sponsor:** Dana-Farber Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-10
- **Primary completion:** 2025-12
- **Final completion:** 2025-12
- **Target enrollment:** 26 (ACTUAL)
- **Last updated:** 2026-02-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02909777

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02909777, "Trial of CUDC-907 in Children and Young Adults With Relapsed or Refractory Solid Tumors, CNS Tumors, or Lymphoma". Retrieved via AI Analytics 2026-08-12 from https://api.ai-analytics.org/clinical/NCT02909777. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*